Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Philip J Mease; Richard B Warren; Peter Nash; Jean-Marie Grouin; Nikos Lyris; Damon Willems; Vanessa Taieb; Jason Eells; Iain B McInnes

doi:10.1007/s40744-024-00706-w

Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Rheumatol Ther. 2024 Oct;11(5):1403-1412. doi: 10.1007/s40744-024-00706-w. Epub 2024 Aug 9.

Authors

Philip J Mease¹, Richard B Warren², Peter Nash³, Jean-Marie Grouin⁴, Nikos Lyris⁵, Damon Willems⁶, Vanessa Taieb⁷, Jason Eells⁵, Iain B McInnes⁸

Affiliations

¹ Swedish Medical Center/Providence St. Joseph Health and University of Washington, 601 Broadway, Seattle, WA, 98122, USA. pmease@phillipmease.com.
² Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK.
³ School of Medicine, Griffith University School of Medicine, Brisbane, QLD, Australia.
⁴ University of Rouen, Rouen, France.
⁵ UCB Pharma, Slough, UK.
⁶ UCB Pharma, Brussels, Belgium.
⁷ UCB Pharma, Colombes, France.
⁸ College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

Abstract

Introduction: The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR) was assessed at 52 weeks (Wk52) using matching-adjusted indirect comparisons (MAIC).

Methods: Relevant trials were systematically identified. For patients who were bDMARD naïve, individual patient data (IPD) from BE OPTIMAL (NCT03895203; N = 431) were matched with summary data from KEEPsAKE-1 (NCT03675308; N = 483). For patients who were TNFi-IR, IPD from BE COMPLETE (NCT03896581; N = 267) were matched with summary data from the TNFi-IR patient subgroup in KEEPsAKE-2 (NCT03671148; N = 106). To adjust for cross-trial differences, patients from the bimekizumab trials were re-weighted to match the baseline characteristics of patients in the risankizumab trials. Adjustment variables were selected based on expert consensus (n = 5) and adherence to established MAIC guidelines. Recalculated bimekizumab Wk52 outcomes for American College of Rheumatology (ACR) 20/50/70 response criteria and minimal disease activity (MDA) index (non-responder imputation) were compared with risankizumab outcomes via non-placebo-adjusted comparisons.

Results: In patients who were bDMARD naïve, bimekizumab had a significantly greater likelihood of response than risankizumab at Wk52 for ACR50 (odds ratio [95% confidence interval]: 1.52 [1.11, 2.09]) and ACR70 (1.80 [1.29, 2.51]). In patients who were TNFi-IR, bimekizumab had a significantly greater likelihood of response than risankizumab at Wk52 for ACR20 (1.78 [1.08, 2.96]), ACR50 (3.05 [1.74, 5.32]), ACR70 (3.69 [1.82, 7.46]), and MDA (2.43 [1.37, 4.32]).

Conclusions: Using MAIC, bimekizumab demonstrated a greater likelihood of efficacy in most ACR and MDA outcomes than risankizumab in patients with PsA who were bDMARD naïve and TNFi-IR at Wk52.

Trial registration: NCT03895203, NCT03896581, NCT03675308, NCT03671148.

Keywords: ACR; Bimekizumab; Biologics; IL-17; IL-23; MAIC; MDA; Psoriatic arthritis; Risankizumab.

Associated data

ClinicalTrials.gov/NCT03895203
ClinicalTrials.gov/NCT03896581
ClinicalTrials.gov/NCT03675308
ClinicalTrials.gov/NCT03671148